Edition:
United States

ReNeuron Group PLC (RQE.L)

RQE.L on London Stock Exchange

1.95GBp
18 Aug 2017
Change (% chg)

0.00 (+0.00%)
Prev Close
1.95
Open
1.95
Day's High
--
Day's Low
--
Volume
1,958,305
Avg. Vol
3,401,896
52-wk High
3.67
52-wk Low
1.60

RQE.L

Chart for RQE.L

About

ReNeuron Group plc is a clinical-stage company. The Company, through its subsidiaries, is engaged in researching and developing cell-based therapies. The Company's products are allogeneic. Its CTX stem cell therapy is used for the treatment of patients left disabled by the effects of a stroke. Its human retinal progenitor cells... (more)

Overall

Beta: 0.74
Market Cap(Mil.): £61.71
Shares Outstanding(Mil.): 3,164.62
Dividend: --
Yield (%): --

Financials

  RQE.L Industry Sector
P/E (TTM): -- 79.67 32.70
EPS (TTM): -0.00 -- --
ROI: -25.78 2.87 14.88
ROE: -25.78 5.20 16.12

BRIEF-FDA approves Reneuron's cryopreserved formulation of retinal stem cell therapy candidate​

* ‍FDA approves cryopreserved formulation of reneuron's retinal stem cell therapy candidate​ Source text for Eikon: Further company coverage: (Reporting By London Bureau)

Jun 19 2017

Earnings vs. Estimates